Biopharma Leads Healthcare Portfolio 2020-2021

Clearly, biopharma stocks, both large and small, led the way to outperformance within healthcare. But Q4 2020 was very speculative, so we expect that the momentum will ebb in 2021 in a shift to large-caps.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.